Literature DB >> 11553209

Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis.

S Mehmet1, G Quan, S Thomas, D Goldsmith.   

Abstract

AIM: Diabetes is now the commonest cause of end-stage renal failure, so there are many diabetic patients receiving dialysis therapy. There are several important ways in which dialysis practice can impinge unfavourably on glucose control. This study focuses on the interaction between maltose-derived metabolites in a new peritoneal dialysis fluid and blood glucose measurements using reagent sticks that depend on the glucose dehydrogenase method. CASE REPORT: We report the cases of three patients, with insulin-treated diabetes and end-stage renal disease treated with peritoneal dialysis, who experienced symptomatic hypoglycaemia with inaccurate glucose readings on reagent strips when converted to icodextrin.
CONCLUSION: Careful teamwork between diabetes and renal physicians and specialist nurses is highly desirable to achieve good glucose control in a group of patients at particular risk of microvascular and macrovascular complications.

Entities:  

Mesh:

Year:  2001        PMID: 11553209     DOI: 10.1046/j.0742-3071.2001.00556.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  4 in total

1.  Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid.

Authors:  Stephen G Riley; James Chess; Kieron L Donovan; John D Williams
Journal:  BMJ       Date:  2003-09-13

Review 2.  Icodextrin: a review of its use in peritoneal dialysis.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Unrecognized hypoglycemia due to maltodextrin interference with bedside glucometry.

Authors:  Barbara M Kirrane; Elizabeth A Duthie; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2009-03

4.  Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children.

Authors:  Graham Woodrow; Stanley L Fan; Christopher Reid; Jeannette Denning; Andrew Neil Pyrah
Journal:  BMC Nephrol       Date:  2017-11-16       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.